Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,078,354
  • Shares Outstanding, K 65,118
  • Annual Sales, $ 75,620 K
  • Annual Income, $ -72,700 K
  • EBIT $ 9 M
  • EBITDA $ 17 M
  • 60-Month Beta 1.60
  • Price/Sales 14.84
  • Price/Cash Flow N/A
  • Price/Book 4.27

Options Overview Details

View History
  • Implied Volatility 119.48% (+38.41%)
  • Historical Volatility 72.08%
  • IV Percentile 44%
  • IV Rank 13.19%
  • IV High 421.76% on 04/04/25
  • IV Low 73.56% on 06/10/25
  • Expected Move (DTE 7) 1.24 (7.49%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 1.60
  • Today's Open Interest 7,137
  • Open Int (30-Day) 7,262
  • Expected Range 15.32 to 17.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.51
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -295.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.94 +27.98%
on 11/18/25
18.15 -8.76%
on 12/08/25
+2.24 (+15.64%)
since 11/11/25
3-Month
4.80 +245.36%
on 09/12/25
18.15 -8.76%
on 12/08/25
+11.67 (+238.65%)
since 09/11/25
52-Week
3.50 +373.14%
on 04/07/25
18.15 -8.76%
on 12/08/25
+8.05 (+94.59%)
since 12/11/24

Most Recent Stories

More News
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis...

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics: Q3 Earnings Snapshot

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise...

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model  Data...

GLUE : 16.56 (-3.89%)
Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

GLUE : 16.56 (-3.89%)
SDZNY : 74.4100 (+0.20%)
NVS : 132.36 (+0.89%)
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s  growing preclinical immunology...

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics: Q2 Earnings Snapshot

GLUE : 16.56 (-3.89%)
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome;...

GLUE : 16.56 (-3.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 18.58
2nd Resistance Point 18.17
1st Resistance Point 17.36
Last Price 16.56
1st Support Level 16.14
2nd Support Level 15.73
3rd Support Level 14.92

See More

52-Week High 18.15
Last Price 16.56
Fibonacci 61.8% 12.55
Fibonacci 50% 10.82
Fibonacci 38.2% 9.10
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar